In parallel with clinical trial data, IHMA conducts other laboratory studies that are also an important part of a regulatory filing. These studies carefully investigate various aspects of drug-organism interactions and may be undertaken throughout the product’s development process. Such studies include, but may not be limited to, bacterial killing, drug resistance development, drug interactions and quality control guidelines.